Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia
نویسندگان
چکیده
منابع مشابه
Monitoring molecular response in chronic myeloid leukemia.
Before the advent of tyrosine kinase inhibitor (TKI) therapy, the evaluation of hematologic and cytogenetic responses was sufficient to gauge treatment efficacy in patients with chronic myeloid leukemia. However, with more potent TKI therapies, the majority of patients achieve complete cytogenetic response. Furthermore, deeper molecular responses are now commonly achieved, necessitating a relia...
متن کاملMolecular monitoring of response in patients with chronic myeloid leukemia.
PURPOSE To discuss the importance of regular, consistent use of molecular testing to monitor treatment response and minimal residual disease in patients with chronic myeloid leukemia (CML), as recommended in established practice guidelines. DESIGN This review outlines the efficacy of BCR-ABL1 tyrosine kinase inhibitors (TKIs) in eliciting significant treatment responses in patients with CML; ...
متن کاملMolecular Monitoring and Treatment of Chronic Myeloid Leukemia (CML)
The advances in the treatment strategies in CML epitomize the concept of personalized medicine. These rapid developments towards cure of CML are acutely dependent on our ability to monitor therapeutic response to the drugs and fine-tune the therapy to the challenges posed by drug resistance from development of target site mutations. The fundamental requirement for success of targeted therapy in...
متن کاملChronic myeloid leukemia: molecular monitoring in clinical practice.
The role of molecular monitoring for patients with chronic myeloid leukemia (CML) is multifaceted. Milestone measurements up to 18 months of first-line imatinib therapy are prognostic and provide warning signals of suboptimal response. Serial measurements for patients with a complete cytogenetic response determine ongoing treatment efficacy or signal pending relapse. The pattern of molecular an...
متن کاملMolecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate
The BCR-ABL fusion gene product is a constitutively activated tyrosine kinase, which is fundamental in the pathogenesis of chronic myeloid leukemia (CML). Imatinib mesylate (imatinib, Glivec® or Gleevec®), a small molecule inhibitor of the BCR-ABL tyrosine kinase, is now the first-line treatment for all newly diagnosed chronic phase CML patients. Imatinib treatment results in a high frequency o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2016
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v128.22.3072.3072